MGMT and acute myeloid leukemia: This may possibly be explained by higher percentage of AML cases in the cohort, varying disease status (heterogeneity) at the time of HSCT and partly explained by the altered expression profiles of the MGMT and its regulation by methylation status of its promoter in cancer cells.